Patents Examined by Dameron L. Jones
  • Patent number: 8101157
    Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are targeting ligands that bind an irradiated tumor and therapeutic and diagnostic methods that employ the disclosed targeting ligands.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: January 24, 2012
    Assignee: Vanderbilt University
    Inventor: Dennis E. Hallahan
  • Patent number: 7875258
    Abstract: One aspect of the invention relates to novel complexes of technetium (Tc) with various heteroaromatic ligands, e.g., pyridyl and imidazolyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to novel pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium complexes are also described. Another aspect of the invention relates to novel pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: January 25, 2011
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Kevin P. Maresca
  • Patent number: 7608240
    Abstract: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: October 27, 2009
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: Dan A. Buzatu, Jon G. Wilkes, Dwight Miller, Jerry A. Darsey, Tom Heinze, Alex Biris, Richard Berger, Mark Diggs
  • Patent number: 7407645
    Abstract: The present invention is directed to bioconjugates of complexes represented by the formula: wherein R, R?, R1, R?1, R2, R?2, R3, R?3, R4, R?4, R5, R?5, R6, R?6, R7, R?7, R8, R?8, R9, R?9, M, X, Y, Z and n are defined herein for use as contrast agents in diagnostic imaging.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: August 5, 2008
    Assignee: Metaphore Pharmaceuticals, Inc.
    Inventors: William L. Neumann, Dennis P. Riley, Randy H. Weiss, Susan L. Henke, Patrick J Lennon, Karl W. Aston
  • Patent number: 7384977
    Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: June 10, 2008
    Assignee: PG-TXL Company, L.P.
    Inventors: Chun Li, Sidney Wallace, Dong-Fang Yu, David J. Yang
  • Patent number: 7385042
    Abstract: One embodiment provides a composition comprising a) a compound of formula I: wherein R1, X and n have any of the values described in the specification, or a pharmaceutically acceptable salt thereof; b) a radionuclide; and c) a radioprotectant.
    Type: Grant
    Filed: July 13, 2006
    Date of Patent: June 10, 2008
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventor: Alan R. Fritzberg
  • Patent number: 7385041
    Abstract: A novel dual functioning excipient for metal chelate contrast agents is disclosed. The present excipient, Xm[X?(L?)]n, which is the calcium or zinc salt of the calcium or zinc complex of an organic ligand, enhances safety in that it is able to scavenge both free metal ions and free organic ligand.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: June 10, 2008
    Assignee: Bracco International B.V.
    Inventors: C. Allen Chang, Krishan Kumar, Michael F. Tweedle
  • Patent number: 7384624
    Abstract: Oral contrast compositions are used as an aid for CAT scans and are ideally fast-flowing and good tasting for assisting in quick preparation of a patient in today's extremely active and busy emergency rooms. An oral contrast used for CAT scans of the esophagus, stomach, duodenum, jejunum, small intestines, colon and rectum is formed from water, diatrizoate meglumine, diatrizoate sodium, preservatives and flavorings.
    Type: Grant
    Filed: December 27, 2004
    Date of Patent: June 10, 2008
    Inventor: James Raines
  • Patent number: 7381399
    Abstract: One aspect of the invention relates to novel complexes of technetium (Tc) with various heteroaromatic ligands, e.g., pyridyl and imidazolyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to novel pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium complexes are also described. Another aspect of the invention relates to novel pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: June 3, 2008
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Kevin P. Maresca
  • Patent number: 7381400
    Abstract: A one-step procedure for sentinel lymph node identification and biopsy using a single compound, a radiolabeled, low molecular weight dye (e.g., 125I-labeled methylene blue). This radiolabled dye is mixed with an unlabeled, similar molecular weight dye (e.g., isosulfan or methylene blue). The mixture is injected at the time of surgery, and rapidly migrates to reach the lymph nodes in less than 20 min, more preferably in less than 15 min and most preferably in less than 10 min. Using rabbits, rapid transit of 125I-methylene blue to regional lymph nodes with limited systemic biodistribution has been confirmed. By admixing small amounts of radiolabeled dye with a large amount of unlabeled dye, the sentinel lymph node identification was similar to that for the prior two-step dual mapping process, but with enhanced SLN localization because of the lower energy gamma emission of 125I as compared with 99mTc.
    Type: Grant
    Filed: July 13, 2004
    Date of Patent: June 3, 2008
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventor: Eugene A. Woltering
  • Patent number: 7378079
    Abstract: The present invention provides novel compounds that bind selectively to cells undergoing perturbations and alterations of the normal organization of their plasma membrane, while binding to a lesser degree to cells having membranes of normal organization, and their uses as diagnostic probes. Said compounds and methods used therein may be useful in medical practice, for applications such as diagnosis of disease and monitoring of response to therapy.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: May 27, 2008
    Assignee: NST Neurosurvival Technologies Ltd.
    Inventors: Ilan Ziv, Anat Shirvan, Sharon Ebner
  • Patent number: 7378077
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: May 27, 2008
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Alan R. Fritzberg, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Patent number: 7371402
    Abstract: There is provided use of a pectin composition to prepare an aqueous composition having high yield stress characteristics without substantial gelation, wherein the pectin composition comprises at least a population of pectin that is calcium sensitive; wherein the pectin composition is capable of imparting high yield stress characteristics to an aqueous composition without causing substantial gelatin of the aqueous composition. There is also provided a standardised acidic aqueous composition comprising a deesterified pectin dissolved in water wherein the pH of the aqueous solution is less than 6, and wherein the deesterified pectin has a degree of esterification from about 50-60% and has a calcium fraction greater than 15; and wherein the amount of the deesterified pectin in the aqueous solution is from about 0.1 to 0.5%.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: May 13, 2008
    Assignee: Danisco A/S
    Inventors: Finn Madsen, Stig Groven
  • Patent number: 7364719
    Abstract: Methods and compounds are described for regulating blood pressure in a subject. Specific embodiments are methods for reversing vasodilation of blood vessels, by administering to a subject a therapeutically effective amount peptide AM(11-22). The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock. Other specific embodiments are methods for reversing vasoconstriction of blood vessels, by administering to a subject a therapeutically effect amount of an inhibitor of AM(11-22), sufficient to reduce hypertension in the subject. Compounds and pharmaceutical compositions are also provided, as are kits.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: April 29, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Frank Cuttitta, Alfredo Martinez, William G. Stetler-Stevenson, Edward J. Unsworth, Juan M. Saavedra
  • Patent number: 7358343
    Abstract: Trimetallic nitride endohedral metallofullerene derivatives and their preparation are described. The trimetallic nitride endohedral metallofullerene derivatives have the general formula A3-nXn@Cm(R) where n ranges from 0 to 3, A and X may be trivalent metals and may be either rare earth metal or group IIIB metals, m is between about 60 and about 200, and R is preferably an organic group. Derivatives where the R group forms cyclized derivatives with the fullerene cage are also described.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: April 15, 2008
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Harry C. Dorn, Erick B. Iezzi, James Duchamp
  • Patent number: 7354568
    Abstract: The invention relates to novel magnetic resonance imaging contrast agents and methods of detecting physiological signals or substances.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: April 8, 2008
    Assignee: California Institute of Technology
    Inventors: Thomas Meade, Scott Fraser, Russell Jacobs
  • Patent number: 7351399
    Abstract: Prodrugs of formula I, their uses, their intermediates, and their method of manufacture are described: and pharmaceutically acceptable prodrugs and salts thereof.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: April 1, 2008
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Mark D. Erion, K. Raja Reddy, Edward D. Robinson, Bheemarao G. Ugarkar
  • Patent number: 7351401
    Abstract: This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: April 1, 2008
    Assignee: University of Pittsburgh
    Inventors: William E. Klunk, Chester A. Mathis, Jr., Yanming Wang
  • Patent number: 7351397
    Abstract: Radiopharmaceutical compositions which are stabilized by addition of a hydrophilic 6-hydroxy-chroman derivative.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: April 1, 2008
    Assignee: CIS bio international
    Inventor: John E. Cyr
  • Patent number: RE40594
    Abstract: The present invention relates to methods for identifying inhibitors of the bitter taste response, and by methods of using such inhibitors to either block the perception of bitterness and/or promote the perception of a sweet taste. The inhibitors of the invention may be used as flavor enhancers in foods and pharmaceuticals. The methods of the invention may further be used to characterize the gustatory perception of novel tastants.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: December 2, 2008
    Assignee: Mount Sinai School of Medicine of New York University
    Inventors: Robert F. Margolskee, Ding Ming